A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.
Also called NCT05486065
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 245 participants
- Sponsor
- Registry
-
NCT05486065 -
2022-000882-41
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Greece, Hungary, Poland, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT05486065. Randomized; double masking; primary purpose treatment. Start 2022-08-08 (actual); primary completion 2023-10-12 (actual). Results posted on 2024-11-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05486065- Content hash
a5c48554d976fa0f59396c04fca66ef2dd289da912a7c83c834f13fd83f8d977